Figure 1.

Cytotoxicity towards human ovarian carcinoma cells. (A) Lipid suspension of cisplatin (cisPt-phosphatidylserine/phosphatidylcholine) (▴), conventional cisplatin (∎), conventional cisplatin mixed with a blank lipid suspension (◻), and blank lipid suspension (dashed line). (B) Variations on the standard protocol, omitting freeze-thaw (▵), omitting phosphatidylserine (엯). (C) Proposed mechanism of nanocapsule formation and cell interaction.
Note: Adapted by permission from Macmillan Publishers Ltd: Nature Medicine,69 copyright 2002.